Medicines Australia

Summary

On 27 March 2020, Medicines Australia (MA) lodged an application for authorisation on behalf of itself and its members, and the Generic and Biosimilar Medicines Association (GBMA) and its members. MA seeks authorisation for an initial period of six months to implement a coordinated strategy in relation to the supply of essential medicines and related supplies in response to the current COVID-19 pandemic. MA also seeks urgent interim authorisation, in light of the current demands on the health system and in order to assist relevant government bodies.

On 3 April 2020, the ACCC granted interim authorisation.

The ACCC invites submissions in relation to the application for authorisation by 27 April 2020. For further information about the application, and how to provide a submission to the ACCC, please refer to the links below.

An indicative timetable is set out below for your information

Indicative date

Stage in assessment process

27 March 2020

Lodgement of application, including request for interim authorisation

3 April 2020

ACCC decision on interim authorisation

6 April 2020

Public consultation begins

27 April 2020

Closing date for submissions

18 May 2020

Applicant responds to issues raised in public consultation process

June/July 2020

ACCC draft determination

July/August 2020

Public consultation on the draft determination including any conference if called

September 2020

Final determination

Applicant(s)

  • Medicines Australia

Authorisation number(s)

  • AA1000486-1

Decisions

Document title Date